Company news

Emyria Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Emyria to Expand Perth Clinic to Meet Growing Demand

August 26, 2025

Avive Health to host Queensland's first Empax clinic in landmark partnership with Emyria

August 13, 2025

Emyria Commences National Expansion with Avive in Brisbane

July 28, 2025

June 2025 Quarterly Activities Report and Appendix 4C

July 28, 2025

Largest Australian Health Insurer to Fund Innovative PTSD Treatment Program

June 18, 2025

Medibank to Fund Emyria's PTSD Program at Perth Clinic

June 18, 2025

PTSD Gains Sustained at 6m Follow-Up, MOU Signed with ANU

May 27, 2025

March 2025 Quarterly Activities Report and Appendix 4C

April 28, 2025

Emyria Opens New Empax Centre to Meet Demand and Payer Needs

April 13, 2025

Emyria Reports Promising 3-Month PTSD Treatment Results

February 3, 2025

December 2024 Quarterly Activities Report and Appendix 4C

January 31, 2025

Leadership Updates

January 21, 2025

Emyria Secures $2.525M in Strongly Supported Placement

November 26, 2024

Response to ASX Price Query

November 12, 2024

Emyria & UWA Partner to License Novel Serotonin Therapies

October 30, 2024

September 2024 Quarterly Activities Report and Appendix 4C

October 29, 2024

Emyria Gains Ethics Endorsement for Psilocybin Program

October 27, 2024

Emyria Shares Interim Success in PTSD Treatment Program

September 2, 2024

Appendix 4E & Annual Report for the Year Ended 30 June 2024

August 30, 2024

June 2024 Quarterly Activities Report and Appendix 4C

July 29, 2024

Emyria, UWA Secure $499K Grant for MDMA Analogue Program

June 30, 2024

Empax Centre Selected As Key Site In Global PTSD Study

June 19, 2024

March 2024 Quarterly Activities Report and Appendix 4C

April 25, 2024

Emyria Receives Bids of $2.3M to Expand Clinical Services

April 23, 2024

Emyria opens Empax Centre to target care gaps in resistant PTSD

April 10, 2024

Emyria Opens Empax Centre to Advance Mental Health Care

April 9, 2024

Emyria Expands Specialist AP Team - First Female for MDMA-AT

April 4, 2024

Emyria, Reach Wellness Enter MDMA-AT Research Agreement

April 2, 2024

Response to ASX Aware Query

March 12, 2024

December 2023 Quarterly Activities Report and Appendix 4C

January 30, 2024

Emyria Receives $2.5M R&D Tax Incentive Refund

January 14, 2024

Emyria Specialist Granted Authorised Prescriber Status

January 9, 2024

Board Changes and Executive Restructuring

November 12, 2023

Emyria Secures Ethics Endorsement for MDMA AP Application

October 29, 2023

Emyria hails strong growth in clinical billings

October 26, 2023

September 2023 Quarterly Activities Report and Appendix 4C

October 25, 2023

Health Canada Approval Received for MDMA Import

October 18, 2023

Emyria's Clinic Achieves Key MDMA-AT Dosing Milestone

October 8, 2023

Completion of Entitlement Offer

October 5, 2023

Emyria set to begin MDMA study after securing local supply

September 26, 2023

Emyria Secures Local MDMA to Start PTSD Trial Dosing

September 20, 2023

Emyria Completes Acquisition of the Pax Centre

September 13, 2023

Emyria provides unique combination of drug development and therapy delivery

September 7, 2023

Strategic Update & Entitlement Offer Presentation

September 5, 2023

Prospectus

September 5, 2023

Emyria Gets $2M Bids, Sets $3.1M Entitlement Offer

September 4, 2023

Appendix 4E Preliminary Financial Report

August 30, 2023

Emyria Launches Ketamine-Assisted Therapy Program

August 7, 2023

Emyria advances development and commercialisation of unique drug products

August 1, 2023

June 2023 Quarterly Activities Report and Appendix 4C

July 31, 2023

← Newer news releases · Older news releases →

Decks

The 5 newest of 27 decks. Every deck is listed under its year.